LENZ Therapeutics
LENZ Therapeutics is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision. Our lead program is an aceclidine based eye drop designed to restore the loss of near vision associated with presbyopia.
Presbyopia
Presbyopia is the gradual and inevitable loss of near vision
Research shows adults over 45 lose on average 1.5 lines of near vision every 6 years1
Most of us first start to notice this as…
- We hold our phones farther from our eyes
- Have difficulty reading a menu in a dimly lit restaurant
Aceclidine
The first and only aceclidine-based eye drop with potential of providing all day seamless vision for the vast majority of presbyopes
- Made possible by aceclidine, our novel active ingredient
- Quickly achieved near vision for on demand needs with a long duration*
- No impact on distance vision in standard and night conditions*
- Potential for broadest target patient population
*Based on Phase 2 study
The Only Pupil Selective Miotic
Aceclidine is the active and new chemical entity in our lead drug
- Unique mode of action
- Targets iris sphincter for pinhole effect
- Predominantly avoids ciliary stimulation preventing unwanted refractive errors
RECENT NEWS
LENZ Therapeutics
LENZ Therapeutics to attend Academy Boston 2021
LENZ Therapeutics CEO Eef Schimmelpennink speaks with RApport about seeking out a new challenge and helping 120 million Americans ditch their reading glasses.
LENZ Therapeutics was recently featured in MSA Partners article "Developing a Treatment for Presbyopia" in Japan